ARS PHARMACEUTICALS INC (SPRY) Stock Income Statement
NASDAQ:SPRY - Nasdaq - US82835W1080 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 89.15M | 30.00K | 1.32M | 0.00 | 0.00 | |||
| Cost Of Goods | 877.00K | N/A | N/A | N/A | N/A | |||
| Gross Profit | 88.27M | N/A | N/A | N/A | N/A | |||
| Operating Expenses | 91.36M | 67.55M | 36.83M | 89.58M | 32.92M | |||
| Research and Development | 19.58M | 20.27M | 18.38M | 61.50M | 24.58M | |||
| Selling, General, and Administrative Expenses | 71.67M | 47.28M | 18.46M | 28.08M | 8.34M | |||
| Operating Income | -3.08M | -67.52M | -35.52M | -89.58M | -32.92M | |||
| Interest Income/Expense | N/A | N/A | -900.00K | 110.00K | -30.00K | |||
| Other Income/Expense | 11.37M | 13.15M | 1.73M | N/A | N/A | |||
| Income Before Taxes | 8.29M | -54.37M | -34.68M | -89.48M | -32.95M | |||
| Income Tax | 288.00K | N/A | N/A | N/A | N/A | |||
| Net Income | 8.00M | -54.37M | -34.68M | -89.48M | -32.95M | |||
| EBITDA | -3.00M | -67.45M | -35.20M | -88.80M | -32.28M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | 0.08 | -0.57 | -0.87 | -2.56 | -0.95 | |||
| Non GAAP EPS | 0.05 | -0.57 | -0.98 | -2.56 | N/A | |||
| Statistics | ||||||||
| Gross Profit Margin | 99.02% | N/A | N/A | N/A | N/A | |||
| Profit Margin | 8.97% | -181216.67% | -2627.27% | N/A | N/A | |||
| Operating Profit Margin | -3.46% | -225066.67% | -2690.91% | N/A | N/A | |||
All data in USD